Study to explore viability of robot-built space outposts made from debris

There’s a lot of perfectly good space junk floating around up there, such as the upper stages of spent rockets. NanoRacks, a company dedicated to democratizing low-earth orbit by supporting innovations like cheap, easily deployed CubeSats, wants to use those in-space structures to build habitats known as Outposts. The Outposts could prove to be crucial infrastructure for commercial space travel and exploration.

Naturally, the heavy lifting — er, weightless shifting — will fall to robots.

Sounds a little far-fetched, to be sure, but NASA is getting behind the idea. The space agency recently chose NanoRacks as one of 13 companies involved in a study of commercial human spaceflight in Low Earth Orbit (LEO). This week, NanoRacks shared some details about its Space Outpost Program and identified strategic study partners supporting its efforts, including Olis Robotics, which makes remote robotics software.

Read more here: https://www.zdnet.com/article/study-to-explore-viability-of-robot-built-space-outposts-made-of-debris/

Seattle Angel Fund rebrands with launch of SeaChange, its largest raise to date

Angel investing is a tricky game. Supporting a startup just getting off the ground takes a lot of work. But after several years spent as a venture capitalist in the Bay Area, Susan Preston, now the managing member at Seattle’s SeaChange Fund, returned to the Pacific Northwest with an idea for how to spot sound bets for seed investments and then nurture their growth.

And a collaborative due diligence process aimed at both fostering consensus among angel investors and encouraging entrepreneurs is at its heart.

Read more about SeaChange’s transformation here: https://pitchbook.com/news/articles/seattle-angel-fund-rebrands-with-launch-of-seachange-its-largest-raise-to-date

GeekWire: SEngine Receives 3.1m Grant to Bring Personalized Cancer Fighting Tech to Patients

Every patient’s cancer is unique and every patient responds to cancer drugs differently. But right now, all patients with the same kind of cancer are treated with the same drugs.

SEngine Precision Medicine is hoping to change that with new platform, called PARIS, that grows and analyzes a patient’s cancer cells to figure out which drugs will work best for them.

Read the rest right here: https://www.geekwire.com/2018/startup-researchers-get-3-1m-grant-bring-personalized-cancer-fighting-tech-patients/

s2s PR Representing Xconomy “What’s Hot in Seattle Biotech” Speakers

We’re proud to have cultivated the speaking engagement for Phase Genomics. CEO Ivan Liachko will present on the convergence of technology and the life sciences on June 12th in Seattle, alongside other biotech innovators such as Adaptive Biotechnologies and Silverback Therapeutics.

Find the details and join us here: https://www.xconomy.com/whats-hot-in-seattle-biotech/speakers/

 

 

SEngine Discovery of Common Link in 28% of all Cancers Makes Medical, Life Science News

Scientists from Cure First and SEngine Precision Medicine discover common link in 28% of all cancers

Read the story here

Testimonial: Opticyte

“s2s PR helped transform our complex medical messaging into a compelling and human story for both investors and potential partners. They helped increase the impact of presentations and branding to bring us closer to our business goals.” – Robert  V. Masterson, CEO Opticyte, Inc

Seattle Business Magazine features SEngine Precision Medicine

SEngine Precision Medicine CEO Dr. Carla Grandori showcases SEngine’s scientific edge in functional precision oncology:

KOMO 4 Appearance: Female Founders Alliance Speaks about Tech and VC Gender Gap

Female Founders Alliance Founder, Leslie Feinzaig speaks with KOMO 4’s Mary Nam about the inaugural Champion Awards honoring advocates for women founders in tech, launching Female Founders Alliance and the rapid international growth of the organization. s2s PR happy to help make the media opportunity a reality.

See the entire clip from the February 2018 appearance here:

Client Voice: The Future of Fighting Cancer

Read SEngine Precision Medicine CEO Dr. Carla Grandori’s article about the future of personalize cancer treatment, Young Lions

https://www.linkedin.com/pulse/young-lions-harnessing-next-generation-technologies-carla/?published=t

Q13 FOX News Covers the Game-Changing Vermouth App

See Founder Jamien McCullum speak about the future of the trust-economy and Vermouth on FOX Q13